NASDAQ: BIOA
Bioage Labs Inc Stock

$4.52+0.10 (+2.26%)
Updated Feb 13, 2025
BIOA Price
$4.52
Fair Value Price
-$0.75
Market Cap
$162.04M
52 Week Low
$3.85
52 Week High
$26.62
P/E
N/A
P/B
0.52x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.08
Operating Cash Flow
N/A
Beta
2.2
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BIOA Overview

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine BIOA's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

C
Value
C
Growth
C
Momentum
D
Sentiment
C
Safety
D
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
BIOA
Ranked
#57 of 63

Top Ranked Stocks in Industry

View Top Pharmaceutical Stocks

Be the first to know about important BIOA news, forecast changes, insider trades & much more!

BIOA News

Overview

Due Diligence Score

Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BIOA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BIOA ($4.52) is overvalued by 699.86% relative to our estimate of its Fair Value price of -$0.75 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BIOA ($4.52) is not significantly undervalued (699.86%) relative to our estimate of its Fair Value price of -$0.75 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BIOA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more BIOA due diligence checks available for Premium users.

Valuation

BIOA fair value

Fair Value of BIOA stock based on Discounted Cash Flow (DCF)

Price
$4.52
Fair Value
-$0.75
Undervalued by
699.86%
BIOA ($4.52) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BIOA ($4.52) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

BIOA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.52x
Industry
2.17x
BIOA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BIOA's financial health

Profit margin

Revenue
$0.0
Net Income
-$23.4M
Profit Margin
0%

Assets to liabilities

Assets
$337.4M
Liabilities
$23.6M
Debt to equity
0.08
BIOA's short-term assets ($336.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIOA's short-term assets ($336.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIOA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$14.9M
Investing
-$305.0k
Financing
$190.7M

BIOA vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
BIOAD$162.04M+2.26%N/A0.52x
OGIC$170.31M0.00%-3.44x0.76x
ZOM$119.55M+1.67%-1.85x0.59x
DERMC$108.42M-0.57%-5.52x9.92x
LFCRD$219.93M+3.85%-11.88x14.24x

Bioage Labs Stock FAQ

What is Bioage Labs's quote symbol?

(NASDAQ: BIOA) Bioage Labs trades on the NASDAQ under the ticker symbol BIOA. Bioage Labs stock quotes can also be displayed as NASDAQ: BIOA.

If you're new to stock investing, here's how to buy Bioage Labs stock.

What is the 52 week high and low for Bioage Labs (NASDAQ: BIOA)?

(NASDAQ: BIOA) Bioage Labs's 52-week high was $26.62, and its 52-week low was $3.85. It is currently -83.02% from its 52-week high and 17.4% from its 52-week low.

How much is Bioage Labs's stock price per share?

(NASDAQ: BIOA) Bioage Labs stock price per share is $4.52 today (as of Feb 13, 2025).

What is Bioage Labs's Market Cap?

(NASDAQ: BIOA) Bioage Labs's market cap is $162.04M, as of Feb 14, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bioage Labs's market cap is calculated by multiplying BIOA's current stock price of $4.52 by BIOA's total outstanding shares of 35,848,738.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.